BGR GOVERNMENT AFFAIRS

Lobbying for ALKERMES, INC. · Biopharmaceutical Company

Filing 1st Quarter - Amendment

1st Quarter (Jan 1 - Mar 31) 2025 · Massachusetts · House · Senate · $50,000.00 income · posted Apr 21, 2025

Lobbying activity 1

Health Issues

Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.